BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver 2019;13:16-24. [PMID: 30400734 DOI: 10.5009/gnl18071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Šamadan L, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:780. [PMID: 34198964 DOI: 10.3390/antibiotics10070780] [Reference Citation Analysis]
2 Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021;21:456. [PMID: 34016040 DOI: 10.1186/s12879-021-06147-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Choi MK, Choi S. In vitro and in vivo anti-clostridial activity of newly isolated Pediococcus acidilactici SPM138 against Clostridium difficile. Anaerobe 2020;61:102146. [PMID: 31887433 DOI: 10.1016/j.anaerobe.2019.102146] [Reference Citation Analysis]
4 Henson MA. Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection. PLoS Comput Biol 2021;17:e1008782. [PMID: 33617526 DOI: 10.1371/journal.pcbi.1008782] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 van Rossen TM, van Dijk LJ, Heymans MW, Dekkers OM, Vandenbroucke-Grauls CMJE, van Beurden YH. External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:1756284820977385. [PMID: 33456500 DOI: 10.1177/1756284820977385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Leung J, Pham S. A Systematic Review of Fecal Microbiota Transplantation Versus Vancomycin for Treatment of Recurrent Clostridioides difficile Infection. Gastroenterol Nurs 2021;44:106-15. [PMID: 33795620 DOI: 10.1097/SGA.0000000000000529] [Reference Citation Analysis]
7 Van der Meer J, Mamouris P, Nassiri V, Vaes B, van den Akker M. Use of antibiotics and colorectal cancer risk: a primary care nested case-control study in Belgium. BMJ Open 2021;11:e053511. [PMID: 34893485 DOI: 10.1136/bmjopen-2021-053511] [Reference Citation Analysis]
8 Abdeen A, Della Valle CJ, Kendoff D, Chen AF. The Paradox of Prosthetic Joint Infection and the Microbiome: Are Some Bacteria Actually Helpful? Arthroplasty Today 2022;13:116-9. [DOI: 10.1016/j.artd.2021.11.011] [Reference Citation Analysis]
9 Zhang RF, Man YX, Bai YY, Shao CH, Liu CM, Wang CH, Lei YX, Wang Y, Jin Y. Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital. J Microbiol Immunol Infect 2021:S1684-1182(21)00016-5. [PMID: 33563561 DOI: 10.1016/j.jmii.2021.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
11 Kulecka M, Waker E, Ambrozkiewicz F, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiol 2021;21:36. [PMID: 33509087 DOI: 10.1186/s12866-021-02090-9] [Reference Citation Analysis]
12 Ramos-Martínez A, Serrano-Martínez F, Pintos I, Valencia-Alijo Á, Gutiérrez-Rojas Á, Cítores MJ, Ortiz-Balbuena J, Royuela A, Martínez-Ruiz R, Sánchez-Romero I, Asensio Á, Múñez E, Plaza A. Effective definition of low humoral response to Clostridioides difficile infection. Anaerobe 2021;72:102475. [PMID: 34752901 DOI: 10.1016/j.anaerobe.2021.102475] [Reference Citation Analysis]
13 Marinescu AR, Lăzureanu V, Laza R, Musta V, Nicolescu N, Cuț TG, Dehelean C, Oancea C, Licker M. Association between ribotype and clinical form of enterocolitis with C. difficile in Western Romania: A 2-year study. Exp Ther Med 2022;23:22. [PMID: 34815774 DOI: 10.3892/etm.2021.10944] [Reference Citation Analysis]
14 Yoon H, Shim HI, Seol M, Shin CM, Park YS, Kim N, Lee DH. Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection. Gut Liver 2021;15:61-9. [PMID: 32839363 DOI: 10.5009/gnl20135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cebrián R, Macia-Valero A, Jati AP, Kuipers OP. Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp. Front Microbiol 2019;10:2154. [PMID: 31616392 DOI: 10.3389/fmicb.2019.02154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L, Chiriac S, Singeap AM, Cuciureanu T, Sfarti C, Stanciu C. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases 2021; 9(33): 10180-10188 [PMID: 34904088 DOI: 10.12998/wjcc.v9.i33.10180] [Reference Citation Analysis]
17 Ramezani Kapourchali F, Glueck B, Han Y, Shapiro D, Fulmer CG, Cresci GAM. A Spore-Forming Probiotic Supplement Improves the Intestinal Immune Response and Protects the Intestinal Health During Recurrent Clostridioides difficile Colonization in Mice. JPEN J Parenter Enteral Nutr 2020;44:1428-38. [PMID: 32495964 DOI: 10.1002/jpen.1851] [Reference Citation Analysis]
18 Kwak S, Choi J, Hink T, Reske KA, Blount K, Jones C, Bost MH, Sun X, Burnham CD, Dubberke ER, Dantas G; CDC Prevention Epicenter Program. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. Microbiome 2020;8:125. [PMID: 32862830 DOI: 10.1186/s40168-020-00907-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Shaffer SR, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, Bernstein CN, Singh H. Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study. CMAJ Open 2020;8:E737-46. [PMID: 33199507 DOI: 10.9778/cmajo.20190191] [Reference Citation Analysis]
20 Furlon JM, Mitchell SJ, Bailey-Kellogg C, Griswold KE. Bioinformatics-driven discovery of novel Clostridioides difficile lysins and experimental comparison with highly active benchmarks. Biotechnol Bioeng 2021;118:2482-92. [PMID: 33748952 DOI: 10.1002/bit.27759] [Reference Citation Analysis]
21 Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453142 DOI: 10.1038/s41575-021-00499-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Feuerstadt P, Stong L, Dahdal DN, Sacks N, Lang K, Nelson WW. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ 2020;23:603-9. [PMID: 31999199 DOI: 10.1080/13696998.2020.1724117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Wu KS, Syue LS, Cheng A, Yen TY, Chen HM, Chiu YH, Hsu YL, Chiu CH, Su TY, Tsai WL, Chen WY, Huang CH, Hung HM, Huang LJ, Kuo HJ, Lin PC, Yang CH, Hong PL, Lee SS, Chen YS, Liu YC, Huang LM; Infectious Diseases Society of Taiwan., Medical Foundation in Memory of Dr. Deh-Lin Cheng., Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education., CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines., 5th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. J Microbiol Immunol Infect 2020;53:191-208. [PMID: 32169531 DOI: 10.1016/j.jmii.2020.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, Nistor-Cseppento DC, Rus M, Pavel FM, Tit DM. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare (Basel) 2020;8:E352. [PMID: 32967323 DOI: 10.3390/healthcare8030352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]